MedTrace Logo

COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults

NCT05950776 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-07-18

No results posted yet for this study

Summary

In this multi-center phase II clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine MVA-SARS-2-S, or placebo.

The aim of the study is to assess the safety and immunogenicity of the candidate vaccine.

Conditions

  • Covid19

Interventions

BIOLOGICAL

MVA-SARS-2-S

Vaccination with MVA-SARS-2-S

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • German Center for Infection Research

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • University Hospital Tuebingen

    collaborator OTHER

  • CTC-NORTH

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Marylyn M Addo, MD · CTC-NORTH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2022-11-02
Completion
2022-11-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950776 on ClinicalTrials.gov